During the R&D event for investors, Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) released new topline data from its Phase 3 pediatrics trial evaluating one year of setmelanotide in patients aged two and below six years with Bardet-Biedl syndrome (BBS) or proopiomelanocortin (POMC) or leptin receptor (LEPR) deficiency obesity. Data highlights: 83.3% of all patients (10 of 12) achieved ≥ 0.2 reduction in BMI-Z score from baseline to week 52;18.4% mean reduction from baseline in BMI at week 52 (N=12);3.04 mean reduction from baseline in BMI-Z score at week 52 (N=12).Rhythm also submitted a Type II v…
